dromlakhani Follow monitoring protocol for transgender females on hormone therapy
STEP 1 — Gather Information
Collect baseline and ongoing data: clinical evaluation for feminization and adverse reactions, serum testosterone and estradiol every 3 months, prolactin annually, serum electrolytes every 3 months if on spironolactone, baseline BMD if indicated, and age-appropriate cancer screening.
STEP 2 — Rule In / Rule Out
Determine if hormone levels are within target range (testosterone <50 ng/dL, estradiol 100–200 pg/mL). If yes, proceed to Step 3; if no, adjust estrogen/anti-androgen dose and recheck levels in 3 months.
STEP 3 — Classify or Stratify
Classify prolactin level: normal (<25 ng/mL) vs elevated (≥25 ng/mL). If elevated, evaluate for prolactinoma and consider reducing estrogen dose; if normal, continue routine monitoring.
STEP 4 — Decide
Based on hormone level adjustment, prolactin evaluation, and BMD/cancer screening needs, implement individualized monitoring plan: repeat hormone labs in 3 months, prolactin annually, electrolytes quarterly if on spironolactone, BMD per risk, and age‑appropriate cancer screening.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on symptoms alone without confirming hormone levels; do not ignore elevated prolactin without further evaluation; do not forget electrolyte monitoring in patients on spironolactone; do not delay BMD testing in high‑risk individuals (age ≥60, non‑compliant, prior fracture); do not omit routine cancer screening per age‑appropriate guidelines.
Concrete Clinical Example
A 22‑year‑old transgender female on estradiol 4 mg oral daily and spironolactone 100 mg daily reports good breast development and no adverse symptoms. Labs: testosterone 45 ng/dL, estradiol 150 pg/mL, prolactin 20 ng/mL, potassium 4.2 mmol/L. Hormone levels are within target, prolactin normal, electrolytes adequate. Plan: continue current regimen, check electrolytes in 3 months, prolactin in 12 months, BMD at baseline (low risk → consider at age 60), and follow cervical/breast cancer screening per guidelines.
Source: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons, Endocrine Society, 2017, https://doi.org/10.1210/jc.2017-01658